<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379989</url>
  </required_header>
  <id_info>
    <org_study_id>ET-D-009-10</org_study_id>
    <nct_id>NCT01379989</nct_id>
  </id_info>
  <brief_title>INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer</brief_title>
  <acronym>INOVATYON</acronym>
  <official_title>Phase III International, Randomized Study of Trabectedin Plus Pegylated Liposomal Doxorubicin (PLD) Versus Carboplatin Plus PLD in Patients With Ovarian Cancer Progressing Within 6-12 Months of Last Platinum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Averion International Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this multicentric, randomised, Phase III study is to demonstrate
      superiority, in terms of survival, of trabectedin and Pegylated Liposomal Doxorubicin (PLD)
      versus carboplatin and PLD in partially-platinum sensitive ovarian cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomised to:

      Arm A: PLD 30 mg/m2 and carboplatin AUC 5; Arm B: PLD 30 mg/m2 and trabectedin 1.1 mg/m2.
      Patients' characteristics: patients over 18 years of age with advanced, progressive ovarian
      cancer 6-12 months after completion of first line or second line treatment with
      platinum-based chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled</time_frame>
    <description>This is an event driven study. The study will continue until 442 events have occurred.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint</time_frame>
    <description>PFS will be measured from the date of randomization to the date of documented PD or death (regardless of cause of death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective RR</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint</time_frame>
    <description>Objective RR will be the best response obtained in any evaluation according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA-125 serological response</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint</time_frame>
    <description>CA-125 serological response will be the best response obtained in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint</time_frame>
    <description>Duration of response: will be calculated from the date of first documentation of response (CR or partial response [PR], whichever occurs first) to the date of documented PD or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to subsequent chemotherapy administration</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint</time_frame>
    <description>The time from randomization to subsequent chemotherapy counted from the administration of subsequent chemotherapy will be evaluated as an exploratory analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS for Subsequent chemotherapies</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint</time_frame>
    <description>the overall survival counted from the administration of subsequent chemotherapy until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS for the Subsequent Chemotherapies</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint</time_frame>
    <description>the progression free survival counted from the administration of subsequent chemotherapy untill disease progression or death whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of serious adverse events (SAEs)</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint</time_frame>
    <description>Number of SAEs for each randomization arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL according to the EORTC QLQ-C30 and QLQ-OV28</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint</time_frame>
    <description>Two PRO instruments will be administered in this study: the EORTC QLQ-C30 and QLQ-OV28.PRO instruments will be completed by the patient at screening (before randomization) and within four weeks after the 6th cycle or at the time of progression, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response to each Subsequent chemotherapy line</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint</time_frame>
    <description>The best response obtained to each Subsequent chemotherapy line calculated as frequency of patients with CR, PR, SD or PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of toxicities, graded according to the NCI-CTAE version 4.0</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint</time_frame>
    <description>Clinical and laboratory toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of toxicities leading to dose delays</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint</time_frame>
    <description>Clinical and laboratory toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of toxicities leading to dose modifications</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint</time_frame>
    <description>Clinical and laboratory toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of toxicities leading to treatment discontinuation</measure>
    <time_frame>This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint</time_frame>
    <description>Clinical and laboratory toxicities</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">588</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Carboplatin plus PLD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/ m2 followed by carboplatin AUC 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trabectedin plus PLD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/m2 infusion followed by trabectedin 1.1 mg/m2 infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 5</description>
    <arm_group_label>Carboplatin plus PLD</arm_group_label>
    <other_name>Carboplatin generic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Lipoxomal Doxorubicin (PLD)</intervention_name>
    <description>PLD 30 mg/m² i.v.</description>
    <arm_group_label>Carboplatin plus PLD</arm_group_label>
    <arm_group_label>Trabectedin plus PLD</arm_group_label>
    <other_name>Caelyx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin</intervention_name>
    <description>trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.</description>
    <arm_group_label>Trabectedin plus PLD</arm_group_label>
    <other_name>Yondelis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female, aged ≥ 18 years

          2. Histologically and/or cytologically proven epithelial ovarian, epithelial fallopian
             tube cancer or primary peritoneal cancer

          3. Progression free interval between six and twelve (6-12) months (calculated from the
             first day of the last cycle of the last platinum-based chemotherapy until the date of
             progression confirmation through radiologic imagery). Patients may have received up to
             two platinum-based chemotherapy lines, of which at least one must have contained a
             taxane

          4. Measurable or evaluable disease confirmed by radiological imaging, such as magnetic
             resonance imaging (MRI), computed tomography (CT) scan, or PET/CT scan at study entry
             (CA-125 rise not supported by radiological evidence of disease is not accepted as
             criteria for defining progression) or histological proven recurrent ovarian cancer
             even in the absence of postoperatively measurable or evaluable lesions.

          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2

          6. Estimated life expectancy ≥ 12 weeks

          7. Patients must be accessible for treatment and follow-up

          8. Adequate organ function within 14 days prior to first cycle as evidenced

          9. Patients must be able to receive dexamethasone or its equivalent, which is required if
             randomly assigned to treatment with trabectedin plus PLD

         10. Informed consent of the patient

        Exclusion Criteria:

          1. Non epithelial ovarian or mixed epithelial/non epithelial tumors (e.g., Mullerian
             tumors)

          2. Patients who did not respond to last platinum-based therapy or in whom last relapse
             occurred &lt; 6 months or &gt; 12 months from the last dose of platinum

          3. Bowel obstruction, sub-occlusive disease or the presence of symptomatic brain
             metastases

          4. Pre-existing grade &gt; 1 motor or sensory neuropathy according to the National Cancer
             Institute Common Toxicity Criteria Adverse Event (NCI-CTCAE) version 4.0

          5. Myocardial infarct within six months before enrolment, New York Association (NYHA)
             Class II or worse heart failure (Appendix 1. The New York Heart Association),
             uncontrolled angina, severe uncontrolled ventricular arrythmias, clinically
             significant pericardial disease, or electrocardiographic evidence of acute ischemic or
             active conduction system abnormalities

          6. History of liver disease

          7. Concurrent severe medical problems or any unstable medical condition unrelated to
             malignancy, which would significantly limit full compliance with the study or expose
             the patient to extreme risk or decreased life expectancy

          8. Breastfeeding women and women of child bearing potential must use effective
             contraception during treatment and 3 months thereafter, which may include prescription
             contraceptives (oral, injection, or patch), intrauterine device, double-barrier method
             or male partner sterilization (not applicable to patients that are surgically sterile)

          9. Prior exposure to trabectedin

         10. Prior resistance to anthracyclines or PLD defined as a progression during
             anthracycline-based chemotherapy or a recurrence within 6 months from its ending

         11. Prior severe PLD related toxicity

         12. Prior exposure to cumulative doses of doxorubicin &gt;400mg/m2 or epirubicin &gt;720mg/m2

         13. Treatment with any investigational product within 30 days prior to inclusion in the
             study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicoletta Colombo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Institute of Oncology (I.E.O), Milan, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus Der Barmherzigen Brueder</name>
      <address>
        <city>Graz</city>
        <state>AT</state>
        <zip>8020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Clinic for Gynaecology and Obstetrics - Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>AT</state>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Klinik Frauenheilkunde AKH</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imeldaziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <state>BE</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <state>BE</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <state>BE</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>BE</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMSE Clinique et Maternité Sainte-Elisabeth</name>
      <address>
        <city>Namur</city>
        <state>BE</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Damiaan</name>
      <address>
        <city>Oostende</city>
        <state>BE</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Voor Oncologie</name>
      <address>
        <city>Turnhout</city>
        <state>BE</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Peltzer La Tourelle (CHPLT)</name>
      <address>
        <city>Verviers</city>
        <state>BE</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dinant Godinne / UCL Namur</name>
      <address>
        <city>Yvoir</city>
        <state>BE</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>DK</state>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <state>FI</state>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital - Kuopio</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin</name>
      <address>
        <city>Berlin</city>
        <state>DE</state>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Waldkrankenhaus Spandau</name>
      <address>
        <city>Berlin</city>
        <state>DE</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Jörg Schilling</name>
      <address>
        <city>Berlin</city>
        <state>DE</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Krebsheilkunde für Frauen</name>
      <address>
        <city>Berlin</city>
        <state>DE</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Netzwerk für Gesundheit GmbH</name>
      <address>
        <city>Berlin</city>
        <state>DE</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <state>DE</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. med. Georg Heinrich Schwerpunktpraxis für Gynäkologische Onkologie</name>
      <address>
        <city>Fürstenwalde</city>
        <state>DE</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kath. Marienkrankenhaus</name>
      <address>
        <city>Hamburg</city>
        <state>DE</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts - Frauenklinik -Tübingen</name>
      <address>
        <city>Heidelberg</city>
        <state>DE</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Krefeld</name>
      <address>
        <city>Krefeld</city>
        <state>DE</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <state>DE</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Brandenburg</name>
      <address>
        <city>Brandenburg an der Havel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsfrauenklinik Dusseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte Evang. Huyssens Stiftung</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Leverkusen gGmbH</name>
      <address>
        <city>Leverkusen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie</name>
      <address>
        <city>Ravensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UFK am Klinikum Suedstadt Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Speyer</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale Umberto Parini</name>
      <address>
        <city>Aosta</city>
        <state>AO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Ospedale Degli Infermi - Biella&quot;</name>
      <address>
        <city>Biella</city>
        <state>BI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. &quot;A.Perrino&quot; ASL Brindisi</name>
      <address>
        <city>Brindisi</city>
        <state>BR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Poliambulanza</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>CN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Valduce</name>
      <address>
        <city>Como</city>
        <state>CO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria &quot;Policlinico- Vittorio Emanuele&quot; P.O. Gaspare Rodolico</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - IRCCS, Meldola e Cesena</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giuseppe - Azienda USL11</name>
      <address>
        <city>Empoli</city>
        <state>FI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale SS Trinità - Sora</name>
      <address>
        <city>Sora</city>
        <state>FR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ente Ospedaliero Ospedali Galliera</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS San Martino IST - Genova</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO della Provincia di Lecco - Ospedale Alessandro Manzoni</name>
      <address>
        <city>Lecco</city>
        <state>LC</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <state>LE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology, Department of Surgery Science</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Ospedali Riuniti Villa Sofia Cervello</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Guglielmo da Saliceto - Piacenza</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale di Prato S. Stefano</name>
      <address>
        <city>Prato</city>
        <state>PO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ricovero e Cura a Carattere Scientifico - Centro Regionale Oncologico Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <state>PZ</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Faenza</name>
      <address>
        <city>Faenza</city>
        <state>RA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Umberto I</name>
      <address>
        <city>Lugo</city>
        <state>RA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Bianchi - Melacrino - Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I, Universitàdi Roma &quot;La Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Infermi</name>
      <address>
        <city>Rimini</city>
        <state>RN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Sondrio</name>
      <address>
        <city>Sondrio</city>
        <state>SO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Santa Chiara</name>
      <address>
        <city>Trento</city>
        <state>TN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Piemontese Per L'Oncologia - IRCCS, Candiolo</name>
      <address>
        <city>Candiolo</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Città della salute e della scienza - OIRM S. Anna</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mauriziano</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Città Della Salute e Della Scienza di Torino - P.O. S. Anna</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Del Ponte - Varese</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.L.S.S. 13 Mirano - Dolo - Noale</name>
      <address>
        <city>Mirano</city>
        <state>VE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacro Cuore Don Calabria</name>
      <address>
        <city>Negrar</city>
        <state>VR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Materdomini</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Napoli Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero A Tortora</name>
      <address>
        <city>Pagani</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARNAS Civico</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura La Maddalena</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Vincenzo</name>
      <address>
        <city>Taormina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL VC Ospedale S. Andrea - Vercelli</name>
      <address>
        <city>Vercelli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>NL</state>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radium Hospitalet Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Alicante</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <state>ES</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d´Oncologia, Hospitalet - Hospitalet de Llobregat</name>
      <address>
        <city>Barcellona</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospitalario Provincial de Castellon</name>
      <address>
        <city>Castèllo</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia de Girona</name>
      <address>
        <city>Girona</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <state>ES</state>
        <zip>25598</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Madrid</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Althaia</name>
      <address>
        <city>Manresa</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario J.M. Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacion Sanitaria y Universitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia - San Sebastian</name>
      <address>
        <city>San Sebastian</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVO Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <state>ES</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen De La Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari De Terrassa</name>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lluis Alcanyis Xativa</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr Peset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <state>CH</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik -Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <state>CH</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Engeried</name>
      <address>
        <city>Bern</city>
        <state>CH</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Frauenheilkunde, Universitätsklinik für Onkologische Medizin - Inselspital</name>
      <address>
        <city>Bern</city>
        <state>CH</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <state>CH</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Frauenfeld</name>
      <address>
        <city>Frauenfeld</city>
        <state>CH</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <state>CH</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Münsterlingen</name>
      <address>
        <city>Münsterlingen</city>
        <state>CH</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <state>CH</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <state>CH</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital</name>
      <address>
        <city>Winterthur</city>
        <state>CH</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik - Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <state>CH</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale Bellinzona e Valli - Istituto Oncologico Della Svizzera Italiana (IOSI)</name>
      <address>
        <city>Bellinzona</city>
        <state>TI</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worthingh Hospital</name>
      <address>
        <city>Worthing</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 1, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

